Penn Davis Mcfarland Inc. Reduces Stake in Gilead Sciences, Inc. (GILD)

Penn Davis Mcfarland Inc. lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 179,606 shares of the biopharmaceutical company’s stock after selling 16,213 shares during the period. Gilead Sciences makes up approximately 3.8% of Penn Davis Mcfarland Inc.’s investment portfolio, making the stock its 8th largest position. Penn Davis Mcfarland Inc.’s holdings in Gilead Sciences were worth $12,713,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Hall Laurie J Trustee raised its stake in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares in the last quarter. Cable Hill Partners LLC raised its stake in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 541 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its stake in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. raised its stake in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares in the last quarter. Finally, Penserra Capital Management LLC raised its stake in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares in the last quarter. Institutional investors own 74.02% of the company’s stock.

Gilead Sciences, Inc. (GILD) traded down 1.12% during mid-day trading on Thursday, reaching $72.53. 3,045,450 shares of the company traded hands. The stock has a market capitalization of $94.72 billion, a PE ratio of 7.88 and a beta of 1.21. The stock has a 50-day moving average of $72.56 and a 200 day moving average of $68.80. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $82.10.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s revenue was down 8.2% on a year-over-year basis. During the same quarter last year, the firm posted $3.08 earnings per share. Equities research analysts expect that Gilead Sciences, Inc. will post $8.76 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.84%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.

ILLEGAL ACTIVITY WARNING: “Penn Davis Mcfarland Inc. Reduces Stake in Gilead Sciences, Inc. (GILD)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.com-unik.info/2017/08/17/penn-davis-mcfarland-inc-reduces-stake-in-gilead-sciences-inc-gild.html.

Several analysts have recently commented on the company. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Jefferies Group LLC reiterated a “hold” rating and set a $83.00 price objective on shares of Gilead Sciences in a report on Thursday, July 27th. Deutsche Bank AG reiterated a “buy” rating and set a $81.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Leerink Swann reiterated a “hold” rating and set a $74.00 price objective on shares of Gilead Sciences in a report on Tuesday, July 25th. Finally, Cowen and Company reiterated an “outperform” rating and set a $90.00 price objective on shares of Gilead Sciences in a report on Thursday, July 27th. Twelve investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences currently has an average rating of “Buy” and an average price target of $80.31.

In other news, EVP Gregg H. Alton sold 40,000 shares of the stock in a transaction on Friday, July 21st. The shares were sold at an average price of $74.00, for a total value of $2,960,000.00. Following the completion of the sale, the executive vice president now owns 137,488 shares of the company’s stock, valued at $10,174,112. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the completion of the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 206,666 shares of company stock worth $15,223,184. 1.30% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit